Product Description
AR-42 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01129193)
Mechanisms of Action: HDAC6 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alison Walker
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Kidney Diseases|Sarcoma|Renal Cell Carcinoma|Acute Myeloid Leukemia|Waldenstrom Macroglobulinemia|Prolymphocytic T-Cell Leukemia|Prolymphocytic B-Cell Leukemia|Follicular Lymphoma|Multiple Myeloma|Neurofibromatosis 2|Neuroma, Acoustic|Neurilemmoma|Lymphomatoid Granulomatosis|Prolymphocytic Leukemia|Immunoblastic Lymphadenopathy|T-Cell Cutaneous Lymphoma|Adult T-Cell Leukemia-Lymphoma|Diffuse Large B-Cell Lymphoma|Intraocular Lymphoma|Burkitt Lymphoma|Large-Cell Immunoblastic Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Extranodal NK-T-Cell Lymphoma|Lymphoma, Non-Hodgkin|Plasmablastic Lymphoma|Chronic Lymphoid Leukemia|Meningioma|Mycosis Fungoides|Leukemia, Plasma Cell|Sezary Syndrome|Mantle-Cell Lymphoma|T-Cell Peripheral Lymphoma|Neurofibromatoses|Large-Cell Anaplastic Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Marginal Zone Lymphoma|Testicular Cancer|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Lymphoproliferative Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
OSU-15004 | P1 |
Completed |
Multiple Myeloma |
2020-11-14 |
|
14-078H | P1 |
Terminated |
Neurofibromatosis 2|Neuroma, Acoustic|Neurilemmoma|Neurofibromatoses|Meningioma |
2017-05-30 |
|
OSU-09102 | P1 |
Completed |
Chronic Lymphoid Leukemia|Prolymphocytic Leukemia|Lymphomatoid Granulomatosis|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Large-Cell Immunoblastic Lymphoma|Immunoblastic Lymphadenopathy|Lymphoproliferative Disorders|Testicular Cancer|Extranodal NK-T-Cell Lymphoma|Lymphoma, Non-Hodgkin|Plasmablastic Lymphoma|Burkitt Lymphoma|Intraocular Lymphoma|T-Cell Peripheral Lymphoma|Large-Cell Anaplastic Lymphoma|Leukemia, Plasma Cell|Mycosis Fungoides|Adult T-Cell Leukemia-Lymphoma|Prolymphocytic B-Cell Leukemia|Diffuse Large B-Cell Lymphoma|B-Cell Marginal Zone Lymphoma|T-Cell Cutaneous Lymphoma|Multiple Myeloma|Mantle-Cell Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Waldenstrom Macroglobulinemia|Prolymphocytic T-Cell Leukemia|Follicular Lymphoma|Sezary Syndrome |
2017-01-07 |
|
MCC-14-10774 | P1 |
Terminated |
Sarcoma|Renal Cell Carcinoma|Kidney Diseases |
2016-11-24 |